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Abstract
Background: The utility of circulating angiogenic cytokines (CAC) as biomarkers in pancreatic cancer has not been
clarified yet. We investigated the expression and prognostic associations of seven CAC in patients with pancreatic
cancer.
Methods: Serum samples were collected preoperatively in patients undergoing surgery for localized pancreatic
cancer (n = 74), metastatic pancreatic cancer (n = 24) or chronic pancreatitis (n = 20) and in healthy controls
(n = 48). Quantitative enzyme-linked immunosorbent assays and multiplex protein arrays were used to determine
circulating levels of VEGF, VEGFR-1, PlGF, PDGF-AA, PDGF-BB, Ang-1 and EGF. Multivariate analyses on cancer-
specific survival were performed with a Cox proportional hazards model.
Results: VEGF (p < 0.0001), PDGF-AA (p < 0.0001), Ang-1 (p = 0.002) and EGF (p < 0.0001) were differentially
expressed in patients with pancreatic cancer compared to healthy controls. The presence of lymph node
metastases was associated with increased levels of all CAC except for PlGF, whereas there were only minor
associations of CAC with other clinicopathologic variables. The multivariate model including the entire angiogenic
panel revealed high levels of circulating PDGF-AA (hazard ratio 4.58; 95% confidence interval 1.43 - 14.69) as
predictor of poor cancer-specific survival, whereas high levels of PDGF-BB (0.15; 0.15 - 0.88), Ang-1 (0.30; 0.10 - 0.93)
and VEGF (0.24; 0.09 - 0.57) were associated with a favorable prognosis.
Conclusion: Circulating levels of certain angiogenic cytokines correlate with patients’ prognosis after resection for
pancreatic cancer, if a panel of several CAC is considered simultaneously. These data should be considered in
future studies evaluating angiogenic factors as prognostic biomarkers and therapeutic targets in patients with
pancreatic cancer.
Background
Pancreatic cancer is ranked within the ten most com-
mon malignancies in both genders, yet it is responsible
for one forth of cancer-related deaths in Western coun-
tries [1]. The poor prognosis of this disease is reflected
by a dismal overall 5-year survival rate of less than 5%.
Surgical resection is the only treatment modality provid-
ing a chance for cure and together with adjuvant
chemotherapy may improve 5-year survival rates to 18 -
25% [2-4]. Similar to other solid malignancies the major-
ity of patients with pancreatic cancer die of tumor
progression and ultimately metastatic disease. It has
become a well-established notion in tumor biology that
tumor growth and progression to metastatic disease are
dependent on the process of angiogenesis, i.e. the
formation of new vasculature. More than 30 years ago,
Folkman already postulated that adequate supply of
oxygen and nutrients in tumors beyond a size of 2 - 3
mm
3 requires new blood vessels (i.e. perfusion), as it
may not be achieved by diffusion alone [5]. The critical
impact of angiogenesis for disease progression in solid
tumors has been proven by data from experimental
studies[6] together with the results of clinical trials that
demonstrated a therapeutic effect of anti-angiogenic
treatment in patients with colorectal cancer [7] and
non-small-cell lung cancer [8].
The role of angiogenesis for disease progression in
patients with pancreatic cancer has, however, remained
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any medium, provided the original work is properly cited.less clear, as has been the potential effectiveness of anti-
angiogenic therapy for this disease [9,10]. Pancreatic
cancers are not grossly vascularized tumors and are
rather characterized by a dense stromal reaction that
might in turn promote tumor invasion [11]. Intriguingly,
most pancreatic cancers display overexpression of angio-
genic molecules including the vascular endothelial
growth factor (VEGF) as the key mediator of tumor
angiogenesis [12-14]. Nonetheless, controlled clinical
trials on bevacizumab, a monoclonal antibody against
VEGF and Cetuximab, a monoclonal antibody against
epidermal growth factor receptor (EGFR), failed to
demonstrate a survival benefit of anti-angiogenic therapy
for patients with pancreatic cancer [15,16]. The failure
of these agents in therapeutic trials for pancreatic cancer
may in part be related to their mode of action targeting
one certain molecule or its receptor. Although angio-
genesis is a highly complex process that results from a
misbalance of various pro- and antiangiogenic mediators
[17,18], studies on the molecular biology underlying
angiogenesis and the prognostic value of angiogenic
cytokines in pancreatic cancer have been limited to a
single or a few molecules.
Angiogenic cytokines are soluble molecules and their
levels in systemic circulation may reflect the overall
angiogenic activity of the tumor. Several studies could
indeed demonstrate circulating angiogenic cytokines as
prognostic biomarkers in patients with various solid
tumors [19-22]. In the present study, we investigated
the expression of CACs in patients undergoing surgery
for pancreatic cancer and compared these CAC levels to
the angiogenic profiles of patients with metastatic and
benign pancreatic diseases. The selection of these cyto-
kines was based on their known key roles in tumor
angiogenesis[23-25]. Furthermore, we evaluated the
prognostic significance of this angiogenic profile consist-
ing of seven CACs in patients with primary pancreatic
cancer.
Methods
The primary study cohort comprised 74 patients who
underwent resection for primary pancreatic cancer at
the Department of General, Visceral and Transplanta-
tion Surgery, University of Heidelberg between
November 2006 and April 2008. These patients had
the histological diagnosis of pancreatic ductal adeno-
carcinoma and underwent R0 or R1 resection. Patients
who received neoadjuvant chemoradiotherapy were
excluded from the analysis, as were patients with a his-
tory of a second malignancy. Furthermore, we excluded
patients with tumors that developed on the basis of
intraductal papillary mucinous neoplasms or mucinous
cystic neoplasms. To evaluate the angiogenic profile
associated with metastatic disease and benign
pancreatic disease, we also enrolled 24 patients who
had synchronous distant metastases revealed at
exploratory laparotomy and 20 patients with chronic
pancreatitis who underwent surgical resection. A
further control group (n = 48) included healthy sub-
jects who had no evidence of acute or chronic disease
and had no surgery within the past 12 months. All
participants gave written informed consent. The study
protocol was approved by the Ethics Committee of the
University of Heidelberg.
Patients were treated as described previously [26].
Pathological specimens were processed using a stan-
dardized protocol [27]. R1 resection was defined, if the
distance of the tumor from the resection margin was ≤
1 mm. Adjuvant chemotherapy with gemcitabine or
5-FU was recommended to all patients who were able
to tolerate it regardless of resection margin status and
tumor stage. Postoperative surveillance was performed
at our outpatient clinics and the European Pancreas
Center (EPC). Follow-up visits were scheduled every
three months in the first two years and every six
months thereafter. A clinical examination, abdominal
ultrasound and routine laboratory testing with evalua-
tion of carbohydrate antigen 19-9 (CA19-9) levels were
carried out at each follow-up visit. A CT scan was per-
formed at three months postoperatively and every
6 months thereafter. To obtain follow-up information
on those patients who were not followed at our insti-
tution we contacted the primary care physicians.
Serum preparation and cytokine detection
On the day of surgery ten milliliter serum separator
tubes were used to collect blood samples through a cen-
tral venous catheter immediately before incision. To
prevent dilution with blocking saline, the first 5 - 7 ml
of the drawn blood were discarded. The blood samples
were then centrifuged at 2.500 × g for 10 minutes to
extract the serum; the serum was stored at -80°C until
analysis. Samples of the control subjects were obtained
via a peripheral vein and then processed as described
above. Serum concentrations of soluble vascular
endothelial growth factor receptor 1 (sVEGFR-1), pla-
cental growth factor (PlGF), platelet-derived endothelial
growth factors AA (PDGF-AA), epidermal growth factor
(EGF) and Angiopoetin-1 (Ang-1) were quantified using
commercially available quantitative sandwich enzyme-
linked immunosorbent assay (ELISA) kits (Quantikine;
R&D Systems, Inc, Minneapolis, MN). All samples were
analyzed in duplicate and processed at the first freeze-
thaw cycle. Optical densities were quantified using a
microtiter plate reader (ELISA Reader 2010, Anthos
Mikrosysteme GmbH, Krefeld, Germany). The serum
concentrations of vascular endothelial growth factor
(VEGF) and platelet-derived endothelial growth factors
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protein arrays (BioRad Laboratories, Hercules, CA,
USA) and a two-laser array reader that simultaneously
quantifies the cytokines of interest. To ensure
sufficient power for subsequent survival analyses the
number of included CAC was restricted to seven
factors. Standard curves and concentrations were
calculated using Bio-Plex Manager 4.1.1.
Statistical analyses
Continuous data were presented as median and
interquartile range and were compared using the Mann-
Whitney U test. Categorical data were expressed as
absolute and relative frequencies. A Spearman correla-
tion coefficient ≥ 0.4 was considered to indicate a rele-
vant correlation. Cancer-specific survival was calculated
from the date of surgery for pancreatic cancer to the
date of death from pancreatic cancer or the date of last
follow-up information. Patients who were alive at the
date of last contact were censored, as were those
patients who were lost to follow-up and those who died
of reasons not related to the disease. Survival curves
were constructed according to the Kaplan-Meier
method. The log-rank test was used for univariate com-
parisons of time-to-event distributions. Multivariate ana-
lyses were performed using Cox proportional hazards
regression analyses. To evaluate independent prognostic
associations of the individual CAC the entire panel was
included in the multivariate model (i.e. regardless of
their associations with survival on univariate analyses).
In addition, clinicopathologic variables with a p-value
< 0.2 on univariate analyses were included in the multi-
variate model. The levels of CAC were dichotomized
using the median value. All p values were two-sided and
ap - v a l u e≤ 0.05 was considered statistically significant.
All analyses were performed using SPSS
® software ver-
sion 17 (SPSS, Chicago, Illinois, USA) and JMP program
version 7 (SAS Institute Inc., Cary, NC, USA).
Results
Table 1 summarizes the clinicopathologic characteristics
of the 74 patients who underwent surgical resection for
pancreatic cancer. There were 37 (50%) men and
37 women with a median age of 67.1 (58.7 - 70.7) years.
The majority of patients had a tumor located in the
pancreatic head (n = 54; 73%), whereas 14 (19%) and
6 (8%) patients had tumors located in the body and tail
of the pancreas, respectively. Final pathological examina-
tion revealed lymph node metastases in 54 (73%)
patients and microscopic margin involvement in 47
(64%) patients. Poorly differentiated tumors were diag-
nosed in 22 (31%) patients. A total of 49 (66%) patients
received adjuvant therapy. Details on the applied
adjuvant chemotherapy protocols are provided in
Additional file 1.
Expression of circulating angiogenic cytokines in
pancreatic cancer and control groups
In patients with primary pancreatic cancer, circulating
levels of VEGF (p < 0.0001) were significantly increased
compared to healthy control subjects, whereas circulat-
ing levels of PDGF-AA (p < 0.0001), Ang-1 (p = 0.002)
and EGF (p < 0.0001) were significantly decreased. The
comparison of the circulating angiogenic profile of
patients with pancreatic cancer and chronic pancreatitis
Table 1 Clinicopathologic characteristics of the study
population
n (%) or median (IQR)
Total, n 74 (100)
Gender
Male 37 (50.0)
Female 37 (50.0)
Age [years] 67.1 (58.7 - 70.7)
Location of the tumor
Pancreatic head 54 (73.0)
Pancreatic body 14 (18.9)
Pancreatic tail 6 (8.1)
CEA level [μg/l] 2.9 (1.5 - 5.5)
CA 19-9 level [μg/l] 137.9 (33.8 - 558.9)
Tumor size
T1/2 2 (2.7)
T3 72 (97.3)
Lymph node status
Positive 54 (73.0)
Negative 20 (27.0)
Resection margin status
R0 27 (36.5)
R1 47 (63.5)
Tumor differentiation
Moderate (G2) 48 (68.6)
Poor (G3) 22 (31.4)
Adjuvant therapy
Yes 49 (66.2)
No 25 (33.8)
CEA, Carcinoembryonic antigen; CA, carbohydrate antigen; IQR, Interquartile
range
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of VEGF (p = 0.05) and lower levels of PDGF-AA
(p < 0.0001) in patients with malignant disease. The
difference in PDGF-BB levels failed to reach statistical
significance in the comparison of primary pancreatic
cancer patients with healthy subjects (p = 0.07) and
patients with chronic pancreatitis (p = 0.08). Certain
CAC were differentially expressed in patients with pri-
mary and metastatic pancreatic cancer. While circulating
levels of PlGF (p = 0.003) and PDGF-AA (p = 0.02)
were significantly higher in patients with metastatic
disease, these patients had lower serum concentrations
of PDGF-BB (p = 0.001) (Figure 1).
Correlation of CAC in patients with primary
pancreatic cancer
The results of the correlation analyses are displayed in
Table 2. There was no correlation between circulating
levels of VEGFR-1 and PlGF with those of other
angiogenic cytokines in patients with primary pancrea-
tic cancer. However, we found positive correlations of
PDGF-AA and Ang-1 with several CAC: PDGF-AA
levels correlated with VEGF (r = 0.437), PDGF-BB
(r = 0.450), Ang-1 (r = 0.755) and EGF (r = 0.429)
levels. Circulating levels of Ang-1 correlated with
VEGF (r = 0.401), PDGF-BB (r = 0.491) and EGF (r =
0.578).
Association of CAC with clinicopathologic parameters
in patients with primary pancreatic cancer
In a further analysis we evaluated, if circulating levels of
angiogenic cytokines were associated with clinical and
pathologic variables of patients with pancreatic cancer
(Table 3). The results of these analyses show these asso-
ciations to be rather moderate. The presence of lymph
node metastases, however, correlated with increased
levels of several CAC such as VEGF (p = 0.02), VEGFR-
1 (p = 0.006), PDGF-AA (p = 0.04), PDGF-BB (p =
0.0008), Ang-1 (p = 0.004) and EGF (p = 0.03).
Prognostic significance of CAC in patients with primary
pancreatic cancer
Patients were followed for a median duration of 19.4
months. A total of 33 (45%) patients died of their dis-
ease during the follow-up period and 7 (9%) patients
were lost to follow-up. These patients were censored at
the date they were lost to follow-up.
To investigate general clinical and pathologic variables
that are associated with survival after resection for pan-
creatic cancer, we initially performed univariate analyses
(Table 4). These analyses revealed poor tumor differen-
tiation (p = 0.02; log-rank test) to be associated with an
unfavorable prognosis, whereas the association of posi-
tive lymph node status (p = 0.13; log-rank test) and R1
resection status (p = 0.08; log-rank test) with survival
Figure 1 Expression of seven circulating angiogenic cytokines in patients with primary pancreatic cancer (M0), metastatic pancreatic
cancer, chronic pancreatitis and healthy control subjects. Data are presented as median and interquartile range (black bars). * p < 0.05; ** p
< 0.01; *** p < 0.001 (Mann-Whitney U test). Comparisons refer to the group of patients with primary pancreatic cancer.
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univariate analyses none of the individual CAC was
associated with patients’ prognosis.
We next constructed a multivariate Cox proportional
hazards model to assess the prognostic value of our
panel of CAC in patients undergoing resection for pan-
creatic cancer. Using the median values to dichotomize
single CAC, this model included the entire panel of
CAC together with clinicopathologic variables that had
a prognostic value on univariate analyses. The results of
this analysis revealed high levels of circulating PDGF-
AA as adverse prognostic factor with respect to cancer-
specific survival (hazard ratio 4.58; 95% confidence
interval 1.43 - 14.69; p = 0.01). Furthermore, this
Table 3 Association of circulating angiogenic factors with clinicopathologic variables in patients with primary
pancreatic cancer
VEGF VEGFR1 PlGF PDGF-A PDGF-B Ang-1 EGF
Age [years]
< 65 38.8
(12.6, 53.6)
86.7
(65.6, 121.9)
11.6
(9.7, 14,7)
2349.2
(1971.9, 3214.9)
7823.3
(5763.4, 10002.4)
32082.5
(27097.9, 40061.8)
261.4
(137.3, 404.4)
≥ 65 30.3
(15.8, 67.8)
76.2
(63.2, 102.8)
11.3
(8.6, 13.9)
2256.1
(1805.9, 3159.1)
7624.3
(4909.1, 11280.5)
27874.6
(20839.6, 34988.1)
229.3
(122.1, 339.6)
Gender
Male 33.7
(12.6, 54.1)
76.5
(64.3, 98.5)
12.1
(9.4, 14.6)
2329.9
(1913.3, 3286.0)
7461.2
(5336.6, 11665.4)
29589.7
(23901.5, 39920.1)
276.1
(152.5, 356.3)
Female 29.8
(15.6, 59.0)
85.6
(63.3, 123.3)
11.3
(7.8, 14.1)
2342.7
(1798.8, 3162.7)
7691.8
(5627.9, 9768.8)
28157.4
(21420.4, 34759.1)
185.1
(102.3, 373.2)
CA 19-9 level [μg/l]
< 37 29.2
(13.9, 47.9)
76.6
(68.7, 99.2)
10.0
(7.4, 14.8)
2224.5
(1889.7, 3077.1)
7685.5
(5662.1, 9890.9)
25991.6
(20353.1, 31308.6)
197.7
(92.6, 283.8)
≥ 37 36.9
(13.9, 73.3)
79.0
(63.3, 114.2)
12.1
(9.3, 14.3)
2342.7
(1840.9, 3342.9)
7556.8
(4851.8, 10790.6)
30517.1
(22698.9, 39237.5)
283.4
(130.6, 400.7)
Lymph node status
Positive 39.6
(17.4, 68.7)*
84.3
(68.9, 120.7)
§
12.1
(9.3, 14.4)
2370.2
(1888.7, 3417.9)*
8658.4
(6787.3, 11406.9)
#
30907.3
(25670.3, 41267.9)
§
286.1
(146.8, 391.3)*
negative 21.3
(8.3, 40.7)
67.2
(56.9, 85.1)
10.2
(8.2, 14.3)
2096.8
(1795.8, 2623.6)
5627.9
(4566.7, 7215.9)
24700.5
(16330.9, 31600.9)
171.6
(84.1, 253.2)
Tumor differentiation
Moderate
(G2)
31.6
(12.8, 55.3)
78.8
(63.1, 119.7)
10.6
(8.5, 13.7)
2336.3
(1869.7, 2850.1)
7693.9
(5448.5, 10587.1)
28568.6
(21839.1, 34451.8)
224.8
(133.4, 333.3)
Poor
(G3)
39.0
(21.2, 66.7)
80.4
(67.7, 100.6)
12.6
(10.1, 15.8)
2561.1
(1853.7, 3491.3)
7756.3
(4608.0, 11545.1)
33120.3
(22580.3, 40538.4)
282.5
(112.2, 472.8)
Value are expressed as median (interquartile range) and compared using the Mann-Whitney U test; CA, carbohydrate antigen; * p < 0.05;
§ p < 0.01;
# p < 0.001
Table 2 Correlation of circulating angiogenic cytokines in patients with primary pancreatic cancer
VEGF VEGFR-1 PlGF PDGF-A PDGF-B Ang-1 EGF
VEGF 1 0.135 0.234 0.437 0.275 0.401 0.271
0.25 0.04 < 0.0001 0.02 0.0005 0.02
VEGFR-1 0.135 1 0.164 0.201 0.270 0.292 0.066
0.25 0.16 0.08 0.02 0.01 0.57
PlGF 0.234 0.164 1 0.299 0.229 0.153 0.134
0.04 0.16 0.01 0.05 0.19 0.25
PDGF-A 0.437 0.201 0.299 1 0.450 0.755 0.429
< 0.0001 0.08 0.01 < 0.0001 < 0.0001 0.0001
PDGF-B 0.275 0.270 0.229 0.450 1 0.491 0.206
0.02 0.02 0.05 < 0.0001 < 0.0001 0.08
Ang-1 0.401 0.292 0.153 0.755 0.491 1 0.578
0.0005 0.01 0.19 < 0.0001 < 0.0001 < 0.0001
EGF 0.271 0.066 0.134 0.429 0.206 0.578 1
0.02 0.57 0.25 0.0001 0.08 < 0.0001
The upper value indicates Spearman’s correlation coefficient, whereas the lower value indicates the p-value. Relevant correlations are highlighted in bold figures.
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(HR 0.24; 95% CI 0.09 - 0.57; p = 0.002), PDGF-BB (HR
0.15; 95% CI 0.15 - 0.88; p = 0.02) and Ang-1 (HR 0.30;
95% CI 0.10 - 0.93; p = 0.04) of being associated with a
favorable prognosis (Table 5). Figure 2 shows the
Kaplan-Meier plots of CAC that had significant associa-
tions with cancer-specific survival on multivariate
analyses.
Discussion
The present study provides a comprehensive analysis of
the expression and prognostic associations of CAC in
patients with pancreatic cancer. Including a panel of
seven CAC, the results show that certain CAC such as
VEGF, PDGF-AA, Ang-1 and EGF are differentially
expressed in patients with pancreatic cancer compared
to healthy subjects. Furthermore, we found correlations
among CAC in these patients, in particular to PDGF-
AA and Ang-1. Except for PlGF the levels of all CAC,
moreover, correlated with the presence of lymph node
metastases, whereas there were very little associations
with other clinicopathologic variables. Although the
expression of individual CAC did not correlate with
patients’ survival on univariate analyses, the multivariate
model including all angiogenic factors revealed that
serum levels of VEGF, PDGF-AA, PDGF-BB and Ang-1
correlate with patients’ prognosis, if the whole panel of
seven CAC is considered.
The formation of new vasculature is a complex pro-
cess that is mediated by a variety of cytokines [6].
Table 4 Association of clinicopathologic variables and
circulating angiogenic cytokines with cancer-specific
survival: univariate analyses
n (%) Cancer-specific
survival n (%)
P Value*
Total 74 (100) - -
Gender 0.72
Male 37 (50.0) 19 (51.3)
Female 37 (50.0) 14 (37.8)
Age [years] 0.22
< 65 30 (40.5) 14 (46.7)
≥ 65 44 (59.5) 19 (43.2)
Location of the tumor 0.74
Pancreatic head 54 (73.0) 25 (46.3)
Pancreatic body 14 (18.9) 4 (28.6)
Pancreatic tail 6 (8.1) 4 (66.7)
CA 19-9 level 0.38
<3 7[ μg/l] 20 (27.4) 8 (40.0)
≥ 37 [μg/l] 53 (72.6) 25 (47.2)
CEA level 0.59
< 2.5 [μg/l] 33 (45.2) 14 (42.4)
≥ 2.5 [μg/l] 40 (54.8) 19 (47.5)
Lymph node status 0.13
N0 54 (73.0) 26 (48.1)
N1 20 (27.0) 7 (35.0)
Tumor differentiation 0.02
Moderate (G2) 48 (68.6) 20 (41.7)
Poor (G3) 22 (31.4) 12 (54.5)
Resection margin status 0.08
R0 27 (36.5) 8 (29.6)
R1 47 (63.5) 25 (53.2)
VEGF 0.19
≥ 32.1 37 (50.0) 14 (37.8)
< 32.1 37 (50.0) 19 (51.3)
VEGFR-1 0.51
≥ 78.5 37 (50.0) 15 (40.5)
< 78.5 37 (50.0) 18 (48.6)
PlGF 0.84
≥ 11.4 37 (50.0) 18 (48.6)
< 11.4 37 (50.0) 15 (40.5)
PDGF-AA 0.53
≥ 2336.3 37 (50.0) 19 (51.3)
< 2336.3 37 (50.0) 14 (37.8)
PDGF-BB 0.10
≥ 7624.3 37 (50.0) 13 (35.1)
< 7624.3 37 (50.0) 20 (54.1)
Ang-1 0.53
≥ 29202.1 37 (50.0) 15 (40.5)
< 29202.1 37 (50.0) 18 (48.7)
EGF 0.26
≥ 234.2 37 (50.0) 17 (45.9)
< 234.2 37 (50.0) 16 (43.2)
* log-rank test; CEA, Carcinoembryonic antigen; CA, carbohydrate antigen.
Table 5 Multivariate analysis of factors associated with
cancer-specific survival
Variable Category Hazard
ratio
95%
confidence
interval
P
value*
Resection
margin status
R1 vs. R0 1.86 0.69 - 5.04 0.22
Lymph node
status
Positive vs.
negative
2.09 0.68 - 6.46 0.19
Tumor
differentiation
Poor (G3) vs.
moderate (G2)
2.27 0.97 - 5.32 0.06
VEGF [pg/ml] ≥ 32.1 vs. < 32.1 0.24 0.09 - 0.57 0.002
VEGFR-1
[pg/ml]
≥ 78.5 vs. < 78.5 1.52 0.63 - 3.64 0.35
PlGF [pg/ml] ≥ 11.4 vs. < 11.4 0.87 0.35 - 2.12 0.76
PDGF-AA
[pg/ml]
≥ 2336.3
vs. < 2336.3
4.58 1.43 - 14.69 0.01
PDGF-BB
[pg/ml]
≥ 7624.3 vs. <
7624.3
0.36 0.15 - 0.88 0.02
Ang-1 [pg/ml] ≥ 29202.1
vs. < 29202.1
0.30 0.10 - 0.93 0.04
EGF [pg/ml] ≥ 234.2
vs. < 234.2
1.92 0.81 - 4.54 0.14
*Cox proportional hazards regression model
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tumor angiogenesis in solid human malignancies revealed
various factors involved in this process, little is known
about the interplay of these factors, in particular with
respect to pancreatic cancer. The majority of experimen-
t a la sw e l la st r a n s l a t i o n a ls t u d i e sh a v ei n v e s t i g a t e d
expression and biological function of a single or very few
angiogenic molecules. Our analyses, however, show mul-
tiple correlations between the different angiogenic cyto-
kines and thus suggest that their biological functions in
vivo should not be considered independently of each
other, as should not be their utility in clinical practice.
This notion is supported by the finding that none of the
analyzed CAC correlated with patients’ prognosis on uni-
variate analyses, whereas four of these factors were signif-
icantly associated with survival on multivariate analysis
including all angiogenic cytokines together with known
clinicopathologic prognostic factors.
Owing to the fundamental role of angiogenesis for the
growth and metastatic progression of tumors, angiogenic
cytokines have been proposed as targets for systemic
therapy. Furthermore, they may serve as biomarkers to
predict the response or resistance to chemotherapy or
anti-angiogenic therapy [28,29]. To date, however, there
is no validated biological marker to accurately select
cancer patients for systemic therapy [28]. One should
consider that the majority of available studies did not
investigate a panel of markers. Together with these data
our findings suggest that the lack of one single predic-
tive biomarker may be due to the complex interaction
and involvement of various factors and due to a strong
biologic and prognostic correlation between these fac-
tors. In a recently published study, Kopetz et al. exam-
ined changes of various circulating cytokines in 43
patients receiving anti-angiogenic therapy with bevacizu-
mab for metastatic colorectal cancer and found several
of these factors to be increased prior to radiological
development of progressive disease [30]. While these
data also indicate that the assessment of multiple factors
provides more accurate information, further studies are
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Figure 2 Kaplan-Meier plots of circulating angiogenic cytokines that had significant associations with cancer-specific survival on
multivariate analyses. P-values refer to the results of univariate analyses (log-rank test).
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in other types of malignancies.
Although the lack of studies assessing multiple angio-
genic factors holds true for most solid tumors, it might be
of particular interest in pancreatic cancer owing to the
controversial role of angiogenesis in this disease. Despite
its aggressive behavior and the known overexpression of
angiogenic factors, pancreatic cancer is not a strongly vas-
cularized tumor. In line with previous studies [12-14] our
data demonstrated VEGF, a key regulator of tumor angio-
genesis [31], to be overexpressed in patients with pancrea-
tic cancer. The exact biological role of VEGF and its
interplay with other angiogenic cytokines in pancreatic
cancer remains poorly understood and the value of VEGF
as predictor of outcome in patients with pancreatic cancer
is controversial [12,14,32-36]. Our finding of an inverse
correlation of circulating VEGF levels with outcome is
contradictory to studies that reported a positive correla-
tion of VEGF levels with patients’ survival and may in part
be explained by differences in methodology. Some of these
studies included patients with overt metastases, did not
confirm this finding by multivariate analysis and examined
expression of VEGF in tissue samples. Most importantly,
the prognostic value of VEGF was commonly assessed
independently of other CAC. Our data, however, indicate
an inverse prognostic value of circulating VEGF in case
further angiogenic cytokines are considered and, more-
over, suggest that in pancreatic cancer angiogenesis is dri-
v e nl e s ss t r o n g l yb yV E G Fb u tb ya l t e r n a t i v ec y t o k i n e s .
This hypothesis is further supported by the results of clini-
cal trials in patients with this disease that demonstrated
moderate to low activity [37,38] and failed to demonstrate
a survival benefit of anti-VEGF therapy [15].
Our analyses back the role of PDGFs in the molecular
biology of angiogenesis in pancreatic cancer. The PDGF
signaling pathway includes four ligands (PDGF-A, -B,
-C, -D) and two receptors (PDGFR-a and -ß) that act as
dimers and are involved in various physiological func-
tions in embryonic develop m e n ta n dw o u n dh e a l i n g
[39]. While experimental data show PDGF signaling also
to be involved in tumor growth, angiogenesis and
metastasis of various cancers including pancreatic
cancer [40-43], there is limited data on its biological
relevance in humans. We here show that circulating
PDGF-AA correlates with circulating levels of several
angiogenic factors and high levels of circulating PDGF-
AA are associated with poor survival in patients with
pancreatic cancer and thus confirm data showing that
high PDGF-AA mRNA expression levels in pancreatic
tumors are correlated to shorted survival [36]. While
PDGF-AA expression has already been shown to corre-
late with poor prognosis in other tumor entities [44,45],
we also found an inverse correlation of circulating
PDGF-BB levels with patients’ survival. This finding is
in line with experimental studies that demonstrated
PDGF-BB overexpression to inhibit tumor growth in
pancreatic and colorectal tumor models by increasing
the pericyte content of the tumor microenvironment
[46,47]. The opposed effects of PDGF-AA and PDGF-
BB on tumor progression in pancreatic cancer is also
supported by our finding that these cytokines are up-
and down-regulated in patients with metastatic disease
compared to patients with primary pancreatic cancer.
Ang-1 and Ang-2 are the two major ligands of the
endothelial cell-specific tyrosine kinase receptor Tie-2. It
is generally accepted that Ang-1 and 2 have important
functions in the development and stabilization of vascula-
ture [48,49], though their exact role in tumor angiogenesis
and progression remains incompletely understood [50,51].
This may in part may be explained by the complexity of
agonistic and antagonistic ligands for the same receptor
that, moreover, act in concert with each other and other
mediators such as VEGF [52-54]. There is, however,
increasing experimental data demonstrating that overex-
pression of Ang-1 inhibits neovascularization and tumor
growth in various tumor models by promoting vascular
stabilization and maturation [55-58]. In line with these
data, clinical studies on patients with colorectal and pan-
creatic cancer revealed decreased tissue expression of
Ang-1 and increased expression of Ang-2 [59,60], which
was, moreover, revealed as an adverse prognostic marker
in colorectal cancer [61,62]. While there is limited data on
the biological role of Angiopoietins in pancreatic cancer,
our results also demonstrated decreased levels of circulat-
ing Ang-1 in patients with this disease. Furthermore, we
show for the first time that Ang-1 levels correlate inversely
with patients’ prognosis and thus confirm the above precli-
nical data that Ang-1 inhibits tumor progression. Owing
to its proposed involvement in vascular normalization by
anti-angiogenic therapy [63] our data support the notion
of Ang-1 as predictive biomarker of response which
should be the subject of future studies.
Conclusions
The present study analyzed the expression and biologi-
cal relevance of seven CAC in patients with pancreatic
cancer. The results indicate that the serum levels of
certain angiogenic cytokines correlate with patients’
prognosis after resection for pancreatic cancer, if a
panel of several CAC is considered simultaneously.
Based on these data future studies on the bioloigical
role of CAC should not be limited to single molecules.
The inverse correlation of certain CAC with survival
m a yi n d i c a t ew h ya n t i - a n g i o genic therapy has failed in
patients with this disease. Furthermore, the prognostic
relevance of several CAC within the analyzed panel may
support the notion of multi-targeted anti-angiogenic
therapy in patients with pancreatic cancer.
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